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Abstract. Optical spectroscopy has been proposed as an accurate and low-cost alternative for detection of cervical
intraepithelial neoplasia. We previously published an algorithm using optical spectroscopy as an adjunct to colpo-
scopy and found good accuracy (sensitivity ¼ 1.00 [95% confidence interval ðCIÞ ¼ 0.92 to 1.00], specificity ¼
0.71 [95% CI ¼ 0.62 to 0.79]). Those results used measurements taken by expert colposcopists as well as the col-
poscopy diagnosis. In this study, we trained and tested an algorithm for the detection of cervical intraepithelial
neoplasia (i.e., identifying those patients who had histology reading CIN 2 or worse) that did not include the colpo-
scopic diagnosis. Furthermore, we explored the interaction between spectroscopy and colposcopy, examining
the importance of probe placement expertise. The colposcopic diagnosis-independent spectroscopy algorithm
had a sensitivity of 0.98 (95% CI ¼ 0.89 to 1.00) and a specificity of 0.62 (95% CI ¼ 0.52 to 0.71). The difference
in the partial area under the ROC curves between spectroscopy with and without the colposcopic diagnosis was
statistically significant at the patient level (p ¼ 0.05) but not the site level (p ¼ 0.13). The results suggest that the
device has high accuracy over a wide range of provider accuracy and hence could plausibly be implemented by
providers with limited training. © 2012 Society of Photo-Optical Instrumentation Engineers (SPIE). [DOI: 10.1117/1.JBO.17.4.047002]
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1 Introduction
Cervical cancer is the second most common cancer in women
worldwide and a leading cause of death, particularly in
low-resource areas without screening programs.1 GLOBOCAN
data from 2008 show that 80% of new cervical cancer incidence
and mortality will occur in low-resource settings.2 Organized
screening programs have decreased the morbidity and mortality
of cervical cancer in all geographical regions since their intro-
duction.3 To make an impact, screening programs appropriate
for low-resource settings should be developed.4,5
Organized screening programs in high-resource settings have
been based on the use of the Papanicolaou smear, a cytologic
sampling of the cervix.3 If abnormal, a second visit is required
for a colposcopy in which the cervix is visualized under 3.5
to 15 fold magnification. Typically acetic acid at 5 to 6% is used
as a contrast agent, and the cervix is viewed using white
and green light. The green light enhances the recognition of
abnormal vasculature.6 Colposcopically directed biopsies are
performed, and the patient returns for a third visit for treatment.
While treatments have varied over the last 50 years, they can be
summarized as either “ablative” in which no specimen is
obtained or “excisional” in which the tissue is removed for his-
topathological analysis. Either treatment results in two-year cure
rates for pre-cancers of 85 to 90%.7 Invasive cancers are treated
with radical hysterectomy, radiation therapy, chemotherapy, or
combinations. Detection in the precancerous phase results in
tangible survival and little morbidity.
The most important advance in cervical cancer etio-
pathogenesis is the establishment of a causal link to the human
papillomavirus (HPV).8,9 HPV has found to be causal in the
development of cervical cancer. This finding has resulted in
two major advances in the field of cervical cancer control
and prevention: HPV testing and an HPV vaccine. There are
over 60 types of HPV that infect the cervix, and among them
some types are associated with cervical cancer while other
are associated with warts.10,11 Studies worldwide have demon-
strated that types 16 and 18 account for 70% of invasive cancers.
Two preventative vaccines have been developed and both
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for diagnosis and screening in the United States, and recent
guidelines from the U.S. Preventive Services Task Force suggest
that HPV testing is not cost-effective in the United States. A
prospective cohort study is being conducted in the province
of British Columbia to evaluate the use of HPV testing
in predicting recurrence of pre-invasive lesions. Thus the role
of HPV testing in the developed world, where abundant
resources have been spent on cervical cancer screening, remains
unclear.
The International Agency for Research in Cancer (IARC),
part of the World Health Organization, has led the international
effort to address cervical screening in low- and middle-income
countries. It has published reviews addressing the subject,
guidelines for care, and manuals for cervical cancer screening
and treatment. They have analyzed the distribution of HPV
types worldwide in order to assess the adequacy of the vaccine.
Furthermore, they have conducted provocative studies of alter-
native strategies to Papanicolaou testing such as visual inspec-
tion with acetic acid with (VIAM) and without magnification
(VIA), visual inspection with Lugol’s Iodine (VILI), and
HPV testing with the Qiagen test.
Sankaranarayanan, from the IARC, conducted a randomized
trial of three strategies in rural India: no increased intervention,
cytological screening, and VIA and demonstrated that both the
cytology arm and VIA were superior to no increased interven-
tion.14–16 Further analysis yielded results showing that the most
cost-effective strategy was VIA.17–19 Sankaranarayanan later
conducted a randomized trial of the Papanicolaou test, VIA,
and HPV testing with the Qiagen test in rural India and con-
cluded the HPV test was most effective in detecting cervical can-
cer and increasing lives saved.9 This study suggests there may be
a role for HPV testing in the low- and middle-income country
setting. At the present time, the Qiagen test may cost as much as
$30 while a more affordable version called “Care HPV” is
undergoing pilot testing in selected countries. While the role
and cost of HPV testing is a moving target, VIA followed by
immediate treatment, if appropriate, is being disseminated in
many countries.15,20 One issue with the studies conducted by
Sankaranarayanan and others studying VIA, the Papanicolaou
smear, and HPV testing is that only the patients with abnorm-
alities (detected by the screening tests) received further diagnos-
tic studies. This is referred to as “diagnostic bias” or verification
bias in the epidemiologic literature. When every patient in the
sample is not biopsied (i.e., doesn’t have the gold standard test),
there is no way to calculate a true sensitivity or specificity
because the denominator contains only those patients with
abnormalities rather than every patient in the trial. One can
adjust for verification bias; however, one must assume that
the positive and negative predictive values in people who had
the gold standard procedure (those who screened positive)
are the same as the positive and negative predictive values in
people who did not have the gold standard procedure (those
who did not screen positive). This is unlikely to hold true
in the case of prescreening for HPVand only sending those posi-
tive for diagnostic procedures. Furthermore, VIA is likely to
suffer from low specificity. Thus there remains a need for
cost-effective see-and-treat strategies in the low-resource setting
for cervical cancer that are more cost-effective, e.g., a test that is
significantly more effective than VIA yet not much more
expensive.
There are three major obstacles to controlling cervical cancer
in the developing world: 1) the HPV vaccine is expensive
(though reductions in prices may make it affordable) and
addresses 70% of the types that are known to cause cancer; 2)
an increase in the quantity and quality of trained health
care workers is needed to perform a cytology-based screening
program, Colposcopy, VIA, or any technology that involves see
and treat; and 3) there is a need for a revamped electrical and
water infrastructure in many areas. Other important obstacles
include: 1) dissemination of the vaccine, which has been
slow in the United States;21 2) lack of sufficient understanding
of HPV types outside of the developed world; 3) lack of trained
personnel in cytology, histopathology, and surgical oncology;
and 4) absence of functional cancer registries and plans for
follow-up of patients.
Figure 1 shows the screening and diagnostic paradigms for
both the high- and low-resource settings that are clinically
necessary to have an impact on cervical cancer. An automated
pathway that could eliminate unnecessary biopsies and confirm
and differentiate high-grade disease from cancer would be
of great value in the high-resource setting because it would
save valuable health care dollars. To be cost-effective in the
low-resource setting, the strategy must be deployable in an
environment without electricity, be as cost-effective as visual
inspection with acetic acid, and be usable by nurses or trained
health care workers.
A new generation of inexpensive, miniature optical sensors
has been developed to measure the interaction of light with
tissue. Optical spectroscopy has shown that tissue fluorescence
spectra contain information about the metabolic activity of
epithelial cells. As precancer and cancer develop in the epithe-
lia of the colon,22 esophagus,23 bladder,24 bronchus,25 and
cervix,26–41 there are resulting changes in the metabolic activity
of the tissue. Specifically, NADH, FAD, and collagen are
fluorophores that change in concentration as lesions become
more dysplastic.42–44 Reflectance spectroscopy uses white
light to probe tissue changes that correlate well with precan-
cerous and cancerous changes in tissue morphology. Biologic
plausibility studies have demonstrated that reflected white
light scatters more as chromatin increases in density in the
nucleus, and that the changes in vasculature are evident in
reflectance spectra.45–50
We previously published the results of spectroscopy as an
adjunct to colposcopy, using histopathology with consensus
review as the gold standard, for the detection of cervical
intraepithelial neoplasia (CIN).51 In that study, we created a
classification algorithm to discriminate normal tissue from
neoplastic and precancerous tissue. This algorithm used
spectroscopy measurements as well as the colposcopic diag-
nosis, menopause status, age, oral contraceptive use, and
colposcopic tissue type together as predictors in the model.
The algorithm had an estimated sensitivity of 1.00 [95%
CI ¼ 0.92 to 1.00] and specificity of 0.71 [95% CI ¼ 0.62
to 0.79] for detecting moderate cervical intraepithelial neopla-
sia (CIN 2) or worse. That work established spectroscopy
could be successfully used as an adjunct to colposcopy.
By comparison, in the diagnostic study sample, colposcopy
had a sensitivity of 98% and specificity of 45%.52 A
previous study by Cantor et al. showed that the increased
specificity of spectroscopy has the potential to save un-
necessary biopsies through a see-and-treat at one visit and
be cost-effective.53,54 This new study investigates the perfor-
mance of the device by a “colposcopic diagnosis naïve”
provider.
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2 Material and Methods
2.1 Overview of Study Procedures
Patients were recruited either from a screening population with
no self-reported history of abnormal Papanicolaou smears or a
diagnostic population who were referred with an abnormal
Papanicolaou smear or had previous treatment for CIN at
three clinical locations. Each patient received a Papanicolaou
smear and colposcopic examination of the cervix. Following
colposcopic examination, a fiber-optic probe was placed in gen-
tle contact with the cervix, and spectroscopic measurements
were obtained from one or two normal cervical sites covered
with squamous epithelium and, when visible, one colposcopi-
cally normal cervical site with columnar epithelium. If abnorm-
alities were present and visible, measurements were taken
from two colposcopically abnormal sites. Thus all patients
who presented visible anomalies had a sampling of both
abnormal and normal tissue areas.
The probe interrogated an area 2 mm in diameter on the
cervix. Following spectroscopic measurements, all sites interro-
gated with the fiber-optic probe were biopsied with a biopsy
forceps yielding specimens that were 2 mm long by 1 mm
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Fig. 1 Current and proposed pathways for screening and diagnosis of cervical cancer.
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wide by 1 mm deep, which closely approximated the
measured area.
Details on the study design and the overview of study
procedures can be found in Cantor et al.51
2.2 Gold Standard
Histopathologic sections were initially reviewed clinically by
the pathologist at the respective institution, and a second
time by a study histopathologist who was blinded to the results
of the first review to colposcopy and to all other clinical tests
including the spectroscopy.49 When diagnoses were discrepant,
the specimens were reviewed a third time by the study histo-
pathologist to resolve the discrepancy. The histopathologic
consensus diagnosis was used as the gold standard for the
trial. The goal was to discriminate patients with no abnormalities
to low-grade squamous intraepithelial lesions from those with
moderate to high-grade lesions, carcinoma in situ, or cancer.
Thus we identified those patients with “disease” as “CIN 2
or worse” (i.e., “≥ CIN 2”) including those who had a histology
reading of CIN 2, CIN 3, carcinoma in situ (CIS), and invasive
squamous cancer. Patients were classified as “< CIN 2” if
their histology reading was normal, atypia, inflammation,
HPV-related changes, or CIN 1. We developed an algorithm
to discriminate between the two groups using biographical vari-
ables and spectroscopic measurements. A subset of slides were
reviewed a fourth time by the study pathologists at the MD
Anderson Cancer Center, a fifth time at the British Columbia
Cancer Agency, and a sixth time by a cervical pathologist at
the Brigham and Women’s Hospital, Boston, Massachusetts.
The results of these reviews can be found in Malpica et al.49
The kappa statistics for the diagnosis of CIN 2 and worse
were between 0.80 and 1.00, which represents the highest
categories of agreement.
2.3 Spectroscopic Measurements
We developed research-grade, fiber-optic spectrometers to mea-
sure fluorescence and reflectance spectra from cervical tissue
in vivo. In fluorescence spectroscopy, the tissue is illuminated
by light of a particular wavelength denoted the excitation wave-
length, and light re-emitted at a longer wavelength is denoted
the emission wavelengths. The devices measured fluorescence
emission spectra at 16 different excitation wavelengths ranging
from 330 to 480 nm and collected at a range of emission wave-
lengths from 360 through 800 nm. These data are referred to as
an excitation-emission matrix (EEM).
There were two generations of the device used during the
seven years of the trial. The second-generation device improved
over the first generation in that it was more affordable to
construct and took less time to take measurements. More details
of the devices used during the trial can be found in Freeberg
et al.48 and a full treatment of data processing from the devices
can be found in Marin et al.55
2.4 Biographical Variables
Four biographical variables were used as features in the classi-
fication algorithm: menopausal status, colposcopic tissue type,
hormone use, and age. The study of biographical variables and
their inclusion in algorithms in optical technologies is an
advance in the field. These variables were included because,
in biological plausibility studies of this technology, they were
found to be statistically significant variables that explain varia-
bility in the spectroscopic measurements and because this infor-
mation was available at the time of the clinical visit.28,35,46,56–59
Menopausal status was classified into three categories: pre-,
peri-, and post-menopausal based on a review of each patient’s
current and past menstrual history and comparison with the
laboratory results to ensure consistency. The colposcopic tissue
type, identified by the naked eye, does not require extensive
training and was classified as either columnar or squamous. Hor-
mone use was defined by the use of any of oral contraceptive
pills, hormone replacement therapy, or depo-provera.
2.5 Development of an Algorithm for Optical
Spectroscopy
The overall strategy of the algorithm development was to first
split the data into training and test sets, perform data reduction
on the EEMs, train several algorithms using the data-reduced
EEMs and biographical variables, choose the algorithm with
the highest accuracy, and compute its accuracy on the indepen-
dent data (the test set).
All classification algorithms have tuning parameters that
must be estimated from the data. The process of obtaining
the parameters leads to biased performance toward the data
on which it was trained. To obtain an unbiased estimate of
the performance of an algorithm, the performance needs to
be estimated on an independent set of data. Therefore we
split the data into a training set and a test set, with 70% and
30% in each set, respectively. All measurements within a subject
were either in the training or in the test set. We optimized the
algorithm performance on the training data before applying it to
the test data. Classification algorithms require a sufficient num-
ber of cases of disease and nondisease. Therefore, the data were
from a combination of the screening and diagnostic groups to
provide a sufficient number of patients with disease.
Because we considered multiple algorithms and intended to
select the one with the best classification accuracy on the train-
ing data, we needed a reliable estimate of accuracy based only
on the training data. Rather than split the training data into two
datasets, fivefold cross-validation was conducted within the
training set for each algorithm.51 Some algorithms have more
tuning parameters than others. The inclusion of more parameters
makes an algorithm more susceptible to overtraining, wherein
its performance appears good on the data on which they are
trained, yet they perform poorly on new data.
We explored several options for dimension reduction meth-
ods as inputs for each of the algorithms.51 Two strategies were
employed for principal component analysis: concatenating all of
the measured intensities into a single vector, or using principal
components of the emission spectra for each excitation wave-
length separately. The principal components were computed
from the covariance matrix of the emission spectra from the
individual excitation wavelengths. We kept only the principal
components that accounted for at least 95% of the total variation
within that excitation wavelength. This reduced the dimension
of the measurements to between one and three principal com-
ponents per excitation wavelength.
We applied a variety of classification algorithms to the fea-
tures obtained from the methods of EEM data reduction and the
biographical variables: age, menopausal status, hormone use,
and colposcopic tissue type. The various classification algo-
rithms applied to the training data included various Bayesian
methods, including Bayesian variable selection and naïve
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Bayes, logistic regression with forward and backward variable
selection, random forests, classification trees, neural nets, pena-
lized logistic regression, linear discriminant analysis, nearest
neighbor, linear support vector machines, and kernel support
vector machines.60
Once the classifiers were optimized, we chose the algorithm
that had the highest specificity for 80% sensitivity (as estimated
by fivefold cross-validation on the training set). We used recei-
ver operating characteristic (ROC) curve analysis to summarize
the estimated performance of the selected algorithm.61
We provide details on the logistic regression approach, as this
yielded the best algorithm results as estimated from fivefold
cross-validation with training data. We fit a logistic regression
model to the principal components of the spectroscopic data and
biographical variables and used Akaike’s information criterion
to perform a backward stepwise selection of variables.60
We report both per-site and per-patient results when appro-
priate. The per-patient results were computed by taking the
patient spectroscopy score to be the maximum score among
all sites within that patient. This was compared with the patient’s
disease status, defined as the worst histologic finding among all
sites for the patient.
2.6 Interaction of Spectroscopy with Colposcopy
To examine the interaction of spectroscopy with colposcopy, we
first compared the accuracy of the spectroscopy algorithm with
the colposcopic diagnosis (the results of our previous study51) to
the accuracy of spectroscopy without the colposcopic diagnosis.
The colposcopist identified sites—both normal and abnormal—
of interest upon which to place the probe to obtain spectroscopic
measurements; therefore, the training of a completely colpo-
scopy-independent algorithm for spectroscopy is impossible
since even when the colposcopic diagnosis information is not
used, the knowledge and experience of the colposcopist guides
the placement of the probe. This placement could affect the
quality of the resulting fluorescence measurements. To evaluate
the impact of operator expertise on gathered data, we sought
to compare the accuracy of measurements taken by highly
experienced colposcopists to those gathered by nonexperts.
The level of provider expertise was estimated by their clinical
accuracy in the performance of standard-of-care colposcopy.
This was compared with the accuracy of spectroscopy. A
high degree of correlation between accuracy in colposcopy
and in the results of spectroscopy measurements would suggest
a more substantial impact of operator expertise on the quality of
spectroscopic tissue data.
Each colposcopist’s accuracy was estimated using the whole
data set by computing the percentage of colposcopy diagnoses
that were correct: either correctly identifying a site that had an
abnormal biopsy or giving a negative clinical diagnosis for a site
that had a normal biopsy. We used the percentage correct instead
of ROC methods because the low number of “diseased” patients
per colposcopist does not allow for a proper estimation of
sensitivity. Spectroscopy used the colposcopists’ expertise as
to where to place the probe but not the actual colposcopy diag-
nosis; the accuracy of spectroscopy was similarly estimated
by computing the percentage of measurements that correctly
classified the sample.
To examine the interaction between spectroscopy and colpo-
scopy, we computed the correlation between the spectroscopy
algorithm scores and the ordinal colposcopic diagnosis. Per-
patient accuracies were computed by comparing the maximum
spectroscopy score at the colposcopic negative or positive sites
for each patient to the worst histologic diagnosis for all sites in
that patient. An analysis by tissue site compared spectroscopy to
the histologic diagnosis at that site. This analysis could addition-
ally suggest diagnostic strategies to integrate spectroscopy into
the clinical workflow.
Statistical analysis was performed using the statistical
packages R version 2.6.2 (R Foundation for Statistical Comput-
ing, Vienna, Austria), Matlab® (The MathWorks, Inc., Natick,
MA), Mathematica (Wolfram Research, Inc., Champaign, IL),
and Stata Statistical Software Release 10.1 (StataCorp LP,
College Station, TX). Exact binomial confidence intervals
were calculated for sensitivity and specificity. Correlations
were calculated using Spearman’s rank correlation coefficient.
The Wilcoxon signed-rank test was used to compare the average
difference in paired continuous variables. The test set ROC
curves were compared by constructing bootstrap confidence
intervals of the difference between the smoothed partial areas
under the ROC curves (pAUC).62,63
3 Results
The study yielded usable spectroscopy and biopsies for 735 of
the 850 diagnostic patients and 707 of the 1000 screening
patients. According to tissue histology, 201 of the 735 (27%)
patients had biopsies that showed CIN 2, CIN 3, CIS, or cancer
in the diagnostic group, compared with 12 of the 707 patients
(2%) in the screening group. The test set collected using the
second-generation device had 164 patients (46 diseased and
118 nondiseased). This subset was used to obtain the unbiased
estimates of the accuracy since the second-generation device is
the basis for the design of alpha prototypes that are being used
going forward.
The best algorithm results as estimated from fivefold cross-
validation with training data were obtained using logistic regres-
sion with variable selection applied to the biographical variables
and principal components of the fluorescence data. The final
variables in the model, as chosen using ROC curve analysis,
included all four biographical variables and 23 of the principal
component variables from the spectroscopic data.
Using a by-site sensitivity of 0.80, we identified a cutpoint of
0.1615 for the spectroscopy score on the training set, yielding a
by-patient sensitivity (correctly identifying those patients who
had histology reading CIN 2 or worse) of 0.98 [95% confidence
interval (CI) ¼ 0.89 to 1.00] and a specificity (correctly identi-
fying those patients who had histology reading CIN 1 or better)
of 0.62 (95% CI ¼ 0.52 to 0.71) on the test set using the second-
generation device. Given the prevalence of 16.4% of CIN 2 or
worse in our combined screening and diagnostic and combined
training and test data, the positive predictive value was 0.50, and
the negative predictive value was 0.99.
Figure 2 shows the by-patient boxplot of the spectroscopy
scores on the test set by histologic diagnosis and for the subset
of screening and diagnostic patients separately. The spectro-
scopy scores increase with the severity of disease. Figure 3
shows the results of the by-patient ROC curve analysis of the
spectroscopy algorithm with and without the colposcopic diag-
nosis on the test set for the second-generation device on the test
data. The area under the ROC curve (AUC) for the by-patient
algorithm using spectroscopy and the colposcopic diagnosis was
0.86 (0.81 to 0.90, CI) (previously published in Cantor et al.51)
as compared with an AUC of 0.82 (0.76 to 0.89, CI) for
spectroscopy without the colposcopic diagnosis. Including the
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colposcopic diagnosis in the algorithm improves the sensitivity
and specificity. The by-patient pAUCs in the range of 0.80 to
1.00 sensitivity were statistically significantly different
(pAUC ¼ 0.77 versus 0.65 with and without the colposcopic
diagnosis, respectively, p ¼ 0.05). Figure 4 shows the by-site
results. The by-site AUCs were 0.85 (0.81 to 0.89, CI) and
0.83 (0.79 to 0.87, CI) for spectroscopy with and without
the colposcopic diagnosis, respectively. The by-site pAUCs
were not statistically different (pAUC ¼ 0.66 versus 0.62,
p ¼ 0.13).
The by-site and by-patient results for the test set diagnostic
and screening populations are shown in Figs. 5(a) and 5(b),
respectively. We included the data from the first generation
of device due to the very low prevalence of disease in the screen-
ing population. We observed a decrease in performance of spec-
troscopy in the diagnostic population. Furthermore, Fig. 6
shows the accuracy of spectroscopy when the algorithm was
trained with and without the biographical variables. Adding
the biographical variables increased the accuracy substantially.
3.1 Results of the Role of the Colposcopist’s Expertise
There were measurements from nine different colposcopists in
the test set. We used the combined first- and second-generation
devices to get more precise estimates of accuracy. The percen-
tage of correct classifications for colposcopy ranged from 0.69
to 0.90 with a median of 0.82. The accuracy percentages of
spectroscopy ranged from 0.59 to 1.00 with a median of
0.88. The average difference, in favor of spectroscopy, was
0.06 (p ¼ 0.39, Wilcoxon signed-rank test) with no statistical
difference between the two. A scatter plot of the by-patient
accuracies is shown in Fig. 7. The correlation coefficient
between the two was 0.65 and marginally statistically significant
(p ¼ 0.07, Spearman’s rank correlation coefficient). There is
normal
atypia









































Fig. 2 By-patient boxplot of spectroscopy scores on the test set by histologic diagnosis for (a) combined screening and diagnostic populations (second-
generation device); (b) screening population (first- and second-generation device); and (c) diagnostic population (first- and second-generation device).



















Spectroscopy with colposcopy diagnosis (Cantor, et al.)
Spectroscopy without colposcopy diagnosis (this manuscript)
Fig. 3 By-patient receiver operating characteristic curve analysis of
logistic regression algorithm using spectroscopy with and without the
colposcopic diagnosis on the second-generation device test set.
The partial AUCs for sensitivity between 0.8 and 1.0 were statistically
significantly different (p ¼ 0.05).
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Spectroscopy with colposcopy diagnosis (Cantor, et al.)
Spectroscopy without colposcopy diagnosis (this manuscript)
Fig. 4 By-site receiver operating characteristic curve analysis of
logistic regression algorithm using spectroscopy with and without
the colposcopic diagnosis on the second-generation device test set.
The partial AUCs for sensitivity between 0.8 and 1.0 were not statisti-
cally significantly different (p ¼ 0.13).
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Fig. 5 (a) By-site and (b) by-patient receiver operating characteristic
curve analysis of logistic regression algorithm using spectroscopy with-
out the colposcopic diagnosis, using both first- and second-generation
devices, on test set by study population.



















Spectroscopy with biographical variables
Spectroscopy without biographical variables
Fig. 6 By-patient receiver operating characteristic curve analysis
of logistic regression algorithm using spectroscopy without the
colposcopic diagnosis, with and without the biographical variables
on the second-generation device test set.





































Fig. 7 Scatterplotof theaccuracyofcolposcopy (using thewholedata set)
compared with the accuracy of colpscopically directed but colposcopic
diagnosis-independent spectroscopy (using the second-generation
device test set). The crosshairs on each point give the 95% confidence
interval—the horizontal line is the confidence interval for the accuracy
of colposcopy and the vertical line is for spectroscopy.
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significant overlap in the 95% confidence intervals. Table 1
gives the accuracy, sensitivity, specificity, and numbers of
screening and diagnostic patients by provider.
4 Discussion
Our previous results of optical spectroscopy focused on spectro-
scopy as an adjunct to colposcopy, although expert colposco-
pists are unlikely to be available in low-resource settings.
The classification algorithm used in the previous study was col-
poscopically directed (the colposcopists guided the placement of
the probe onto the cervix), and the colposcopic diagnosis and
colposcopic tissue type were also used as covariates in the clas-
sification model. In the current study we developed an algorithm
for point-probe optical spectroscopy without the colposcopic
diagnosis that yielded operating characteristics with good per-
formance and that has the potential for use in real time. The data
suggest that research-grade point-probe devices lost little accu-
racy without using the colposcopic diagnosis in the algorithm.
Clearly, a device for screening or diagnosis for the low- and mid-
dle-income countries will need to be effective in the hands of
health care workers with less training.
We observed a statistical difference between the by-patient
accuracy of spectroscopy with and without the colposcopic
diagnosis. The ROC curves were similar over the range of
high specificity, and the ROC curve for spectroscopy with
the colposcopic diagnosis had notable improvement in the
range of high sensitivity (Fig. 2). Specifically, the omission
of the colposcopic diagnosis had decreased specificity for the
range of high sensitivity. The by-site ROC curves were not sta-
tistically significantly different (Fig. 3).
We observed a decrease in performance when we added the
first-generation device and broke analysis down by screening
and diagnostic populations. Future studies will explore this
decrease in performance. We hypothesize that it could be due
to differences in the devices or differences in the Vancouver/
Houston populations.
Spectroscopy alone (without the colposcopic diagnosis) gen-
erally had similar accuracy to colposcopy alone. In Fig. 4, about
half of the points are above/or to the left of the diagonal line,
meaning that among the patients seen by each colposcopist,
spectroscopy had similar accuracy to the colposcopic diagnosis.
Assuming that a colposcopist’s accuracy is correlated with accu-
rate detection of regions of interest on the cervix and, hence,
accurate placement of the probe on a diseased site, the colpos-
copist’s expertise was expected to have some effect on the accu-
racy of spectroscopy. We observed a slight upward trend
(p ¼ 0.07) suggesting that the accuracy of the colposcopist
might influence the accuracy of the probe through the probe pla-
cement. However, the accuracies of spectroscopy were relatively
high (median 0.88, range 0.59 to 1.00), and the confidence inter-
vals overlapped considerably. Further follow-up is needed, but
this shows promise for the use of spectroscopy in low-resource
settings where expert colposcopists are not widely available, and
for the possible use of methods of probe placement that rely less
on precise identification of abnormalities prior to spectroscopic
measurement.
The colposcopic tissue type was used as a covariate in the
algorithm and is easily identifiable with limited training.
Basic training in performing a Papanicolaou smear involves
1) understanding that the cervix is composed of two tissues
(squamous and columnar) and 2) obtaining a sample of both
ectocervix and endocervix. The “transformation zone,” the
area in which the squamous epithelium is constantly, throughout
life, growing over the columnar epithelium, is the area most at
risk for the location of lesions. This is thought due to the con-
tinuous growth of tissue and the turnover of cells, leading to
increased risk of mitotic events. The most adequate Papanico-
laou specimens contain cells from both the endocervical canal
and the ecto-cervical area of the transformation zone. Any health
care worker who learns how to perform cervical screening with
Papanicolaou smear or VIA is taught to be aware of both tissue
types and the importance of endo- and ecto-cervical sampling.
Table 1 Frequencies of patients from the screening and diagnostic population evaluated using spectroscopy and colposcopy by each provider. The
spectroscopy accuracies were calculated using both generations of device in the test set. The colposcopy accuracies were calculated using all available











sample size Specificity Sensitivity Accuracy
1 NP 40 24 1.00 0.00 0.98 132 97 0.88 0.48 0.87
2 NP 53 53 0.99 0.00 0.86 175 165 0.84 0.79 0.84
3 NP 48 41 0.99 0.33 0.97 175 121 0.91 0.65 0.90
4 NP 8 0 1.00 NA 1.00 23 0 0.89 NA 0.89
5 NP 5 5 1.00 0.00 0.90 15 18 0.68 0.75 0.69
6 GynOnc 36 48 0.63 0.84 0.68 110 167 0.74 0.68 0.73
7 GynOnc 4 4 0.83 1.00 0.88 14 12 0.77 1.00 0.80
8 MD 3 24 0.42 0.73 0.59 15 58 0.68 0.80 0.71
9 GynOnc 2 15 0.63 0.89 0.76 9 59 0.80 0.88 0.82
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We believe there is a role for optical technologies in the
high-, middle-, and low-income settings. There remain large
expenditures in the high-income setting for the evaluation of
minimally abnormal lesions. The role in the high-income setting
is to decrease costs. The role in low- and middle-income country
is to replace infrastructure on two levels: the need for trained
expertise and to help with low adherence to follow-up.
Costs can be decreased in high-income settings such as the
United States, Canada, and Europe by implementing a few prin-
cipal changes to our current screening and diagnostic system: 1)
decreasing the number of unnecessary treatments; 2) improving
the performance of the current standard of care tests; 3) improv-
ing adherence; 4) increasing the HPV vaccine uptake; and 5)
performing screening in high-risk populations that have
previously never been screened.
The high number of unnecessary treatments is due to over-
evaluation of unimportant lesions that are not likely to progress
to cancer. There is abundant data that atypical and low-grade
Papanicolaou smears are overevaluated. Kurman estimated
that $6 billion were spent annually on the evaluation of atypical
cells of uncertain significance (ASCUS) and low-grade
squamous intraepithelial lesions. Improving the accuracy of
discriminating between high-grade and ASCUS lesions can
decrease costs substantially.
The second change is to improve the performance of our
screening and diagnostic tests. There is a wide variation in
the performance of colposcopy, cytology, and histopathology.
The sensitivity of colposcopy in the ALTS multicenter study
was 0.37 (95% CI 0.33 to 0.42) and specificity 0.90 (95%
CI 0.89 to 0.91). Moreover, the Kappa statistic comparing col-
poscopists in the trial was 0.36 (95% CI 0.33 to 0.39). Benedet
et al. documented the performance of colposcopy in Vancouver,
British Columbia, Canada, and showed a sensitivity of 90% and
specificity of 50% for the diagnosis of high-grade lesions.64
Similarly, in our trials, the sensitivity for the diagnosis of
high-grade lesions in the diagnostic population was found to
be 98% and the specificity 45%.52 The ALTS trial also reported
wide variation in the performance of cytology, colposcopy, and
the reading of histopathologic biopsies (low agreement amongst
providers and sites). Automation can improve the performance
by making a test reproducible.
There is low adherence in the United States and Canada. The
“no-show” rate in the colposcopy clinics in both countries is
50%. Though there are many reasons for this low adherence
rate in the high-income countries, providers must spend time
and resources contacting patients because of their ethical
duty to follow-up abnormalities, established guidelines for
care, and to mitigate the other cost of health care in the United
States (malpractice and litigation).
Despite the introduction of an HPV vaccine in the United
States, Canada, and Europe, screening is still recommended
for prevention of cervical cancer since the vaccines do not
confer protection against all types of HPV that cause cervical
cancer.65–69 The current HPV vaccines cover 70 to 74% of all
HPV types that cause cancer globally. The vaccine costs
approximately $360 in the United States, requires refrigeration,
and is administered over three doses, making it difficult to
deliver the vaccine in the developing world, where it could
have the most impact. The vaccine should be given to men
and women to have an impact on a sexually transmitted disease
and ideally would cover the high-risk HPV types most prevalent
in the population being vaccinated.70 New data concerning
cross-reactivity shows that infection with HPV types 52 and
58 are not well covered by the current vaccine, meaning the
current vaccine does not provide sufficient protection from
these types.71
All these findings led the U.S. Preventive Services Task
Force to conclude that the most cost-effective use of dollars
in the United States would be used to screen women who
have not previously been screened. To address these issues
will require identifying these women and studying why they
have not been screened. A cost-effective device with high
accuracy for diagnosis would have a role in decreasing costs
in this setting.
The role of optical technologies in low- and middle-income
countries is to replace infrastructure on two levels: the need for
trained expertise and to help with low adherence to follow-up.
Creating an inexpensive infrastructure (due to the lack of trained
health care workers, cancer registries, cytologic expertise,
histopathologic expertise, and colposcopy expertise) and
replacing the need for adherence since patients may be seen
only once in their lifetime in the current paradigm of care.
A principal challenge to the implementation of large-scale
cancer screening programs in the developing world is the short-
age of highly trained medical practitioners. Effective cervical
screening programs would benefit greatly from automation
that reduce or obviate the need for expert colposcopists. The
screening model that our future studies will evaluate involves
the use of a multispectral digital colposcope (MDC) to create
an automated or semi-automated method to direct the placement
of a point probe. The spectroscopic probe would then be used to
interrogate the selected area(s) of tissue. This study is a first step
toward evaluating the effectiveness of optical spectroscopy
without the use by an expert colposcopist by excluding the
colposcopic diagnosis in the spectroscopy algorithm and by
exploring the influence of the colposcopist accuracy and, hence,
accuracy of probe placement on the accuracy of the spectro-
scopy measurements attained by that colposcopist. There remain
challenges with the HPV vaccine for deployment in the low
resource setting: coverage of HPV types, cost, refrigeration,
and adherence to three visits.
In the developing world, patient adherence to follow-up
monitoring is even more of a challenge than in the developed
world. A see-and-treat strategy is feasible with a combined
MDC-probe device. Additionally, improving the sensitivity of
the screening and diagnostic process, while maintaining a
relatively high specificity, would benefit these populations.
The goal of our future studies is to use a MDC to direct
the probe placement on the cervix and then use a point probe
to predict the histology of the patient. The results of this
study suggest that the skilled placement of the probe does
not have a significant effect on the accuracy of spectroscopy
and, hence, shows promise for the feasibility of being able to
implement spectroscopy using an automated or semi-automated
MDC algorithm for the selection of tissue sites to measure using
the point probe.
A major strength of this study is that we have performed
biopsies of all sites, and thus we have the gold standard
for all patients’ diagnoses, which alleviates the problem of
verification bias. A study limitation is the difficulty to quantify
the importance of the probe placement in the spectroscopy
algorithm as we still do not have automated algorithms for
probe placement. Each provider’s probe placement accuracy
was estimated based on his colposcopic diagnosis accuracy,
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though the precision of these estimates varied depending on the
number of patients seen and the population being evaluated.
Future planned trials will address this. The weakness for
deployment in the low- and middle-income setting is that the
study was conducted in the United States and Canada by expert
colposcopists.
Further research is needed to evaluate the possible clinical
applications of this new technology. For example, a negative
spectroscopy result could lead to the elimination of an unneeded
biopsy. Alternatively, a positive spectroscopy result that con-
firms a positive clinical test, if used in a see-and-treat strategy,
would also lead to the elimination of a biopsy and avoid a further
clinical visit. The spectroscopic device described in this paper
could be used in a clinic to replace biopsies and permit diagnosis
and treatment in a single visit. We hope this model could be a
great benefit to patients in developing countries or underserved
areas of the developed world and reduce costs in the developed
countries.
We plan on training an algorithm for the MDC and correlat-
ing it with the spectroscopic probe to develop a joint algorithm
for the two devices. We will then use this information to
construct a lower-cost device that uses both technologies.
The combination of the MDC with the spectroscopic point
probe could potentially be used by nonexperts, thus addressing
that limitation of our study.
The device of choice in Nigeria and other resource-
challenged settings of Africa, Asia, Oceania, and Latin America
should be battery-powered, low cost, be able to distinguish
infection from neoplasia and view the entire cervix. We are
developing a Diagnostic Imaging Aid (DIA) optimized for
use in low-resource settings based on the MDC.72–75 Figures 8
and 9 show the evolution of cancer imaging devices for high-
resource settings and proposed devices for low-resource
settings, respectively.
A commercial device that had both multispectral images of
the cervix and point probe measurement of specific sites would
provide the best of both approaches. Continuing development of
classification algorithms for use in wide-field and point-probe
devices could produce a combined screening and diagnostic
system with the potential to change the way we control cervical
cancer. Research has suggested that patients prefer screening
and diagnosis using optical spectroscopy when compared
with conventional cytology.76 We hope that forthcoming
developments could bring about a cost-effective and clinically
advantageous cervical cancer control model using a combina-
tion of vaccination and minimally invasive optical technologies.
Fig. 9 Proposed cancer-imaging devices for low-resource settings.
Fig. 8 Evolution of cancer imaging devices for high-resource settings: point-probe spectroscopy (FastEEM) and multispectral digital colposcope (MDC).
The FastEEM2 and FastEEM3 are the first- and second-generation devices, respectively.
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